Copy Link Print Information

Evrisiran

Evrisiran is a prekallikrein synthesis reducer that has been studied for its potential use in hereditary angioedema.

For research use only. We do not sell to patients.

  • CAS No.: 3110420-82-8
  • Formula: C498H665F8N162O313P43S8
  • Molecular Weight:15668.86
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Evrisiran Chemical Structure
    Evrisiran Chemical Structure
CAS No.: 3110420-82-8
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

All Kallikrein Isoforms

More

Keywords

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Evrisiran Chemical Structure
    Evrisiran Chemical Structure RNA, ([1′-de(6-amino-9H-purin-9-yl)]A-(5′→5′)-sp-Um-Gm-Um-Cm-Am-Gm-Um-Um-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)A-Cm-Um-Um-Am-Um-Um-Cm-sp-Am-(3′→3′)-sp-[1′-de(6-amino-9H-purin-9-yl)]A), 3′-[O-[1-[18-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-6,10-bis[2-[[2-[2-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]ethoxy]ethyl]amino]-2-oxoethyl]-1,5,12-trioxo-16-oxa-6,10,13-triazaoctadec-1-yl]-4-piperidinyl] hydrogen phosphorothioate], complex with RNA (Um-[P(R)]-sp-(2′-deoxy-2′-fluoro)G-sp-Am-Am-Um-Am-(2′-deoxy-2′-fluoro)A-Gm-Um-Gm-Am-(2′-deoxy-2′-fluoro)A-Am-(2′-deoxy-2′-fluoro)A-Am-(2′-deoxy-2′-fluoro)C-Um-Gm-Am-sp-Cm-sp-Am) (1:1)
    1/16
  • RNA, ([1′-de(6-amino-9H-purin-9-yl)]A-(5′→5′)-sp-Um-Gm-Um-Cm-Am-Gm-Um-Um-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)A-Cm-Um-Um-Am-Um-Um-Cm-sp-Am-(3′→3′)-sp-[1′-de(6-amino-9H-purin-9-yl)]A), 3′-[O-[1-[18-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-6,10-bis[2-[[2-[2-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]ethoxy]ethyl]amino]-2-oxoethyl]-1,5,12-trioxo-16-oxa-6,10,13-triazaoctadec-1-yl]-4-piperidinyl] hydrogen phosphorothioate], complex with RNA (Um-[P(R)]-sp-(2′-deoxy-2′-fluoro)G-sp-Am-Am-Um-Am-(2′-deoxy-2′-fluoro)A-Gm-Um-Gm-Am-(2′-deoxy-2′-fluoro)A-Am-(2′-deoxy-2′-fluoro)A-Am-(2′-deoxy-2′-fluoro)C-Um-Gm-Am-sp-Cm-sp-Am) (1:1)